<DOC>
	<DOCNO>NCT00692172</DOCNO>
	<brief_summary>An extension study evaluate safety tolerability 3 additional course IM alefacept patient chronic plaque psoriasis previously treat 1 2 course IM alefacept .</brief_summary>
	<brief_title>Open-label Study Evaluate Safety Multiple Courses IM Alefacept During Treatment Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Must receive least 8 injection C99717 study complete final followup visit OR , Must complete C99712 study C99717 interim visit time dose C99717 study close . A subject complete C99712 participate part C99717 , include interim visit , must prior sponsor approval admission C728 Nursing mother , pregnant woman , woman plan become pregnant study exclude . Female patient postmenopausal least 1 year , surgically sterile , willing practice effective contraception study Clinically significant abnormal hematology value history immunosuppressive disorder Serious local infection systemic infection within 3 month prior first dose alefacept A significant change subject 's medical history previous alefacept study Any subject initiate alternative systemic therapy , phototherapy , disallow therapy prior visit 8 study C99712 C99717 Current enrollment investigational study subject receive type drug , biologic , nondrug therapy ( participation registrytype study allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>intramuscular</keyword>
</DOC>